Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in HR+/HER2- Early Breast Cancer with MRD
NCT06517212Phase 2Recruiting
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Nov 2024
- Primary completion
- Aug 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirzepatide in breast cancer, sponsored by Baylor Scott & White Research Institute. Primary endpoints: ctDNA efficacy at 2 years and Distant Disease-Free Survival at 2 years. Started Nov 2024; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06517212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06517212.